BioSpace News Archive

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today provided an update on corporate activities and reported first-quarter 2021 financial results.

Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at the 2021 European Hematology Association (EHA) Virtual Congress.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Nai-Kong V. Cheung, MD, PhD, Enid A. Haupt Endowed Chair, Pediatric Oncology, Memorial Sloan Kettering Cancer Center (“MSK”) will present a research update on the Company’s SADA technology platform at PEGS Boston Virtual Conference

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be presenting at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 and will be hosting virtual one-on-one meetings with investors throughout the day.

Medtronic plc and the Medtronic Foundation announced an additional $3M USD for COVID-19 relief efforts – a combination of financial resources, personal protective equipment donations, and Medtronic employee engagement – focused on underserved areas of India, Brazil, the United States, and other global regions.

Devonian Health Group Inc., a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products is pleased to announce that Dr. André Boulet, President and CEO, will present at the Canada India Healthcare Summit Conference being held virtually from May 20-21, 2021.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that it will sponsor a symposium presenting the latest long-term clinical data on the Reducer™ (“Reducer”), highlighting its easy integration into current cardiovascular and microvascular disease treatments.